Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2020 Mar 19:13:101-104.
doi: 10.2147/IMCRJ.S226422. eCollection 2020.

Graft Loss Following Onset of Schizophrenia Long After Liver Transplantation

Yuta Anraku  1 , Rie Akaho  1 , Satoko Matsui  1 , Akihito Sannomiya  2 , Shohei Fuchinoue  2 , Katsuji Nishimura  1
Affiliations
Case Reports

Graft Loss Following Onset of Schizophrenia Long After Liver Transplantation

Yuta Anraku et al. Int Med Case Rep J. .

Abstract

Information regarding new-onset posttransplant psychotic disorders and their effect on nonadherence and posttransplant outcome is quite limited. We report a case of new-onset posttransplant schizophrenia that led to death. The patient, a woman with Wilson disease but no history of psychiatric problems or a substance use disorder had undergone liver transplantation at age 21. She married subsequently and bore children, being well able to handle her housework, child care, and full-time employment. She continued her medications as prescribed, and good graft function was maintained. At age 41, she experienced an episode of schizophrenia, then graft loss associated with nonadherence to immunosuppressive agents. Death ensued, occurring 6 months after the onset of schizophrenia. This case highlights the possibility that schizophrenia manifesting long after liver transplantation can result in graft loss and death due to medication nonadherence. Thus, awareness of the possibility of this rare clinical scenario is critical.

Keywords: graft loss; liver transplantation; schizophrenia.

PubMed Disclaimer

Conflict of interest statement

Professor Katsuji Nishimura reports grant and/or personal fees from Meiji Seika Pharma, Mochida, Takeda, Yoshitomiyakuhin, Pfizer, Eli Lilly, MSD, Shionogi, Janssen, Eisai, Astellas, Otsuka, Daiichi Sankyo, Nipro, Kissei, Tsumura, Novartis, Mitsubishi Tanabe, Chugai, Dainippon Sumitomo, GlaxoSmithKline, and Mebix, outside the submitted work. The authors report no other conflicts of interest in this work.

References

    1. Price A, Whitwell S, Henderson M. Impact of psychotic disorder on transplant eligibility and outcomes. Curr Opin Organ Transplant. 2014;19:196–200. doi:10.1097/MOT.0000000000000057 - DOI - PubMed
    1. Zimbrean P, Emre S. Patients with psychotic disorders in solid-organ transplant. Prog Transplant. 2015;25:289–296. - PubMed
    1. Kofman T, Pourcine F, Canoui-poitrine F, et al. Safety of renal transplantation in patients with bipolar or psychotic disorders: a retrospective study. Transpl Int. 2018;31:377–385. - PubMed
    1. Molnar MZ, Eason JD, Gaipov A, et al. History of psychosis and mania, and outcomes after kidney transplantation - a retrospective study. Transpl Int. 2018;31:554–565. - PMC - PubMed
    1. Corruble E, Buhl C, Esposito D, et al. Psychosis associated with elevated trough tacrolimus blood concentrations after combined kidney-pancreas transplant. Int J Neuropsychopharmacol. 2006;9:493–494. - PubMed

Publication types

LinkOut - more resources